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Abstract
It is now clearly established that the transfusion of blood from variant CJD (v-CJD) infected individuals can transmit the
disease. Since the number of asymptomatic infected donors remains unresolved, inter-individual v-CJD transmission
through blood and blood derived products is a major public health concern. Current risk assessments for transmission of v-
CJD by blood and blood derived products by transfusion rely on infectious titers measured in rodent models of
Transmissible Spongiform Encephalopathies (TSE) using intra-cerebral (IC) inoculation of blood components. To address the
biological relevance of this approach, we compared the efficiency of TSE transmission by blood and blood components
when administrated either through transfusion in sheep or by intra-cerebral inoculation (IC) in transgenic mice (tg338) over-
expressing ovine PrP. Transfusion of 200 mL of blood from asymptomatic infected donor sheep transmitted prion disease
with 100% efficiency thereby displaying greater virulence than the transfusion of 200 mL of normal blood spiked with brain
homogenate material containing 10
3ID50 as measured by intracerebral inoculation of tg338 mice (ID50 IC in tg338). This was
consistent with a whole blood titer greater than 10
3.6 ID50 IC in tg338 per mL. However, when the same blood samples were
assayed by IC inoculation into tg338 the infectious titers were less than 32 ID per mL. Whereas the transfusion of crude
plasma to sheep transmitted the disease with limited efficacy, White Blood Cells (WBC) displayed a similar ability to whole
blood to infect recipients. Strikingly, fixation of WBC with paraformaldehyde did not affect the infectivity titer as measured
in tg338 but dramatically impaired disease transmission by transfusion in sheep. These results demonstrate that TSE
transmission by blood transfusion can be highly efficient and that this efficiency is more dependent on the viability of
transfused cells than the level of infectivity measured by IC inoculation.
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Introduction
In 1996, a new form of CJD, named variant CJD (v-CJD) was
identified in humans [1,2]. The presence of the v-CJD agent in
lymphoid tissues of patients incubating the disease raised the
possibility of blood borne v-CJD transmission. Since then, four v-
CJD cases were reported in patients transfused with labile blood
productsfromasymptomaticdonorswho later developed v-CJD[3].
Current measures for prevention of v-CJD transmission by
blood products rely on risk assessments based on infectious titers
reported for the blood of rodent models of TSE [4]. These
infectious titers were established by inoculating blood components
by the intracerebral (IC) route in homologous species. All these
experiments concur in indicating that infectivity in the blood of
symptomatic rodents varies between 1 and 10 ID50 per mL and
that both plasma and leukocytes were infectious [5,6,7,8,9,10].
However, the IC inoculation route is unlikely to reflect the
specifics of the transfusion exposure route; i.e. the administration of
large numbers of living cells and a large volume intravenously to
the recipient.
In early 2000, transmission of both experimental BSE and
natural scrapie were reported to occur following transfusion of
whole blood collected in asymptomatic incubating sheep [11,12].
The greater similarity in size between humans and sheep allows
the transfusion of blood volumes in sheep that are closer to those
used in human medicine. Moreover, the pathogenesis of variant
CJD in humans is very similar to that in classical scrapie or BSE in
sheep. As a consequence sheep TSE models are accepted as
relevant for assessing v-CJD transmission risk through the
transfusion route [13,14].
In this study, using a TSE sheep infection model, we
investigated the ability of blood and blood components to transmit
the disease when administered by the transfusion route and
measured their relative infectious titer by IC inoculation in
transgenic mice (tg338) over-expressing ovine PrP. Our findings
show that the disease is transmitted with high efficiency by
transfusion of infected blood and blood components and requires
revision of some of the key assumptions used for assessing the risk
of blood borne transmission of v-CJD.
Materials and Methods
Ethic statement
All animal experiments have been performed in compliance
with our institutional and French national guidelines, in accor-
dance with the European Community Council Directive 86/609/
EEC. The experimental protocol was approved by the INRA
Toulouse/ENVT ethics committee.
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oral inoculation
VRQ/VRQ sheep were produced in a biosecure unit from a
flock that was sourced originally from New Zealand by Veterinary
Laboratory Agency in the United Kingdom (UK). This TSE free
flock is a unique source of VRQ/VRQ animals that are
considered free of classical scrapie [15]. The scrapie inoculum
was prepared from symptomatic VRQ/VRQ sheep experimen-
tally infected with PG127 scrapie isolate. This stock was previously
titrated by end-point dilution in tg338 mice inoculated by the
intracerebral (IC) route [16]. TSE-free Cheviot sheep (6–10
months old) were orally challenged with a 2 g equivalent of brain
(administered as 1% brain homogenate in glucose). Animals were
then observed until the occurrence of clinical signs (around 200
days post inoculation) and euthanized when exhibiting locomotor
signs of the disease that impaired feeding. In this model clinical
phase (first clinical signs occurrence to recumbency) is short (one to
two weeks). After culling, each sheep was necropsied and lymphoid
tissues (spleen, third eye-lid, mesenteric lymph node, prescapular
lymph node, tonsil) were sampled in addition to the CNS for PrP
Sc
detection. The PrP genotype was obtained for every animal by
sequencing Exon 3 of the Prnp gene as previously described [17].
Blood collection and separation
Blood was collected in vigil animals from jugular vein into
Macopharma MSE3500 collection bags. To separate plasma,
buffy coat and red cells, blood units were centrifuged at 3640 rpm
for 12 minutes (including acceleration and deceleration) at 20uCi n
a Jouan LR5-22 centrifuge. For each sample, packed cell volume
and cell numeration were measured using IdeXX Vet-station
automat and Sysmex XT2000i. White blood cells (WBC) were
obtained from buffy coat fraction, by osmotic lysis of erythrocytes
with ACK solution (NH4CL 0,15 M, KHCO3 1 mM, Na2EDTA
0,1 mM, pH 7.4). Briefly, buffy coat (1 volume) was gently mixed
(by rolling tubes) with ACK (1 volume) and incubated for 5 min
RT. WBC were then washed 3 times with 50 mL PBS to remove
erythrocytes debris and plasma.
WBC fixation was performed using paraformaldehyde (PFA)/
PBS solution. WBC cells were re-suspended in a 50 mL conic tube
using 10 mL of PBS and 10 mL of a PBS/PFA 4% solution was
added (final concentration 2%). Tubes were then rolled on bench
during 20 seconds and incubated for 10 min on ice. Cells were
then washed four times in PBS (50 mL) and their morphology
(lack of clumps and cellular integrity) was checked by direct
microscopic examination and flow cytometry.
Transfusion and intravenous administration
Recipient sheep were anesthetized by IV administration of
Ketamine/Diazepam (2 mg and 0.1 mg per kg respectively) and a
catheter (16G) was installed in the jugular vein. This catheter was
used for all transfusions and intravenous administrations of blood
and blood products. Whole blood (200 mL), plasma (100–150 mL)
or WBC (re-suspended in 100 mL 5% glucose) were transfused/
intravenously administered by gravity in individual recipients over
a 30–40 min period.
In the whole blood spiking experiment, the titrated PG127
brain homogenate was diluted in isotonic (5%) glucose solution to
obtain the desired number of Infectious Dose 50 as measured by
IC inoculation in tg338 mice (ID50 IC in tg338) in a 20 mL
volume. Each inoculum was then mixed with 200 mL of freshly
collected whole blood by 30 minutes of continuous rocking before
transfusion back into the same donor sheep. In the whole blood
titration by transfusion route, the required whole blood volumes
were sampled from the collection bag using a sterile syringe and
either transferred into a new pouch or gently re-suspended in a
sterile 5% glucose solution (QSP 200 mL), before administration
(gravity) to recipients. In the WBC experiment, WBC (fresh or
fixed) were gently re-suspended in a 200 mL sterile pouch of
isotonic (5%) glucose before infusion (gravity) over a 20–30 min
period. All transfusions were performed within the 6 hours
following blood collection.
Sheep monitoring and necropsy
Sheep were housed in a category 2 animal facility. Donor and
recipient sheep were kept separated. Contact controls (n=5) were
housed in the same pen as transfusion recipients throughout the
experiment. None displayed any TSE symptoms. Orally inocu-
lated sheep (donors) and transfused sheep (recipients) were
monitored daily. When displaying symptoms that could impair
their ability to feed, the animals were euthanized by an
intravenous injection of T61 (Intervet). Transfused animals that
had not displayed clinical signs after 400–450 days were also
euthanized. Upon completion of the experiment, the contact
controls were also euthanized. All animals were systematically
necropsied and a panel of tissues (brain, spleen, mesenteric lymph
node, tonsil, third eyelid, prescapular lymph node, ileum was
collected. Each sample was divided in two parts, the first one was
formalin fixed for abnormal PrP (PrP
Sc) immunohistochemistry
investigation while the other was snap frozen at 280uC for WB
PrP
Sc detection.
Bioassay in tg338 mice
Bioassay experiments were carried out in transgenic mice
(tg338) over-expressing the VRQ allele of the ovine prion protein
(PrP) [18]. At least six mice were inoculated intracerebrally with
each sample (20 mL). Mice were then monitored for the
appearance of TSE clinical signs. Mice that did not succumb to
TSE were euthanized at 200 days post inoculation (dpi). The last
positive transmission was observed 150 dpi during an end-point
dilution titration of a PG127 brain stock [16]. CNS and spleen
samples collected from each individual animal were tested by
Western blot (WB).
Whole blood, plasma and red blood cell concentrate were high
speed homogenized for 90 seconds (Precess 48- Bertin, France)
Author Summary
In the UK, several v-CJD cases have been identified in
patients that received blood or blood-derived products
prepared from incubating asymptomatic donors. Since
there is no screening test to identify infected donors,
procedural risk reduction measures remain the only
protection against v-CJD transfusion risk. These measures
rely, in part, on the assumptions that (i) the level of
infectivity in blood is low and (ii) the risk of blood borne
transmission is directly correlated with the infectious titer
of blood and blood products. Using a transmissible
spongiform encephalopathy (TSE) animal model, we have
provided evidence that despite a very low infectious titer
in blood as measured by inoculation into brain, the
transfusion of 0.2 mL of blood from asymptomatic
infected donors is sufficient to transmit the disease with
a 100% efficacy. We further demonstrated that this high
efficiency of disease transmission is crucially dependant on
the viability of the transfused white blood cells rather than
on their infectious titer. These findings provide new
insights into the pathogenesis of TSE diseases and require
revision of some of the key assumptions of the v-CJD
blood borne risk assessments.
New Insights in TSE Blood-Borne Transmission Risk
PLoS Pathogens | www.plospathogens.org 2 June 2012 | Volume 8 | Issue 6 | e1002782and inoculated neat (20 ml IC) in tg338 (n=18). No acute toxicity
was observed at inoculation during this experiment. The infectious
titer per mL of blood (number of ID/mL) was estimated by the
limiting dilution titration (application of Poisson model) described
by Brown et al to estimate the infectious titer in TSE affected
rodents’ blood and classically used in this type of study [5,7].
Percentage volume of packed blood cells and plasma were used to
calculate the infectious titer per mL of blood.
WBC corresponding to known quantity of whole blood was high
speed homogenized for 90 seconds (Precess 48- Bertin, France) in
5% glucose solution. The resulting suspension was then titrated by
end point dilution by intracerebral (IC) inoculation of 1/10
successive dilutions into groups of 6 tg338 mice (20 mL/mouse).
The infectious titer (Infectious Dose 50, most likely value and 95%
confidence intervals) were determined by the Spearman-Ka ¨rber
method [19].
According to Fischer [20] and as previously used for Prion
infectivity ID/ID50 comparison [21] one ID50 per mL was
considered in average equivalent to 0.693 ID.
PrP
Sc Western-blot (WB) and immunohistochemistry
A Western blot kit (TeSeE Western Blot, Bio-Rad) was used
following the manufacturer’s recommendations. For each sample,
250 mL of 10% tissue homogenate was subjected to PrP
Sc
extraction. Immunodetection was performed using Sha31 mono-
clonal antibody conjugated to horseradish peroxidase (0,06 mg per
mL) which recognizes amino acids 145–152 (YEDRYYRE) of the
sheep PrP sequence. Peroxidase activity was detected using ECL
substrate (Pierce). Immunohistochemistry was performed as
previously described [22], using 8G8 antibody which specifically
recognises amino acids 95–108 (SQWNKP) of the sheep PrP
protein.
Results
The first experiment was to determine the minimum infectious
dose (ID50 as measured by end point dilution titration in tg338
mice by the IC route) able to transmit TSE infection in sheep by
transfusion. This was done by transfusing groups of two TSE free
VRQ/VRQ recipient sheep with whole blood that had been
spiked with successive 1/10 dilutions of a brain homogenate
prepared from scrapie affected sheep (PG127 isolate). This brain
homogenate had been previously titrated by end point dilution in
tg338 mice, and had a titer of 10
6.6 ID50 IC/g [16]. The lowest
dose resulting in transmission was observed in sheep (1 infection
out of 2 challenged individuals) that were transfused with blood
containing 10
3 ID50 IC in tg338 mice (Table 1). No clinical signs
or abnormal PrP deposition were observed in animals that were
challenged with lower doses and observed for at least 750 days post
challenge.
In parallel, seven VRQ/VRQ sheep were orally challenged
with 10
6.7 ID50 IC in tg338 of the same PG127 brain homogenate
stock. Whole blood samples were collected in four of these animals
(D1–D4) at a late stage of the incubation period (two to five weeks
before clinical onset). 200 mL, 20 mL, 2 mL and 0.2 mL of each
donor’s fresh whole blood were transfused into TSE free VRQ/
VRQ recipients (Table 2). All animals that received 200 mL,
20 mL or 2 mL of blood developed clinical TSE. Three out of the
four recipients that received the 0.2 mL dose also developed
clinical scrapie. The fourth recipient was apparently healthy when
euthanized after 450 days of incubation but had abnormal PrP
depositions in both lymphoid tissues and the central nervous
system.
These results, when considered together, indicate that the
transfusion of 0.2 mL of whole blood transmitted scrapie more
efficiently than the IV administration of 10
3 ID50 IC in tg338
(brain homogenate material). It therefore suggested that in scrapie
infected sheep (close to symptomatic phase) the infectious load per
mL of blood should be higher than 10
3.6 ID50 IC in tg338.
To confirm this estimate, whole blood from three donors (D1 to
D3) and one TSE free control (C1) were each inoculated
intracerebrally into eighteen tg338 mice (20 mL per mouse). An
incomplete attack rate was observed in the inoculated mice
(Table 3) and infectious titers were estimated by a statistical
method previously used to calculate the concentration of infectivity
in blood of TSE infected rodents models [5,23]. Whole blood titers
ranged between 3 and 16 ID IC in tg338 mice per mL (Table 3).
Plasma, red blood cells and WBC were prepared from the same
blood samples. Plasma and RBC were inoculated undiluted
intracerebrally into eighteen tg338 mice. Only a single infection
was observed (D1 plasma). The infectivity titers in plasma and red
blood cells expressed as the equivalent volume of whole blood
were computed to have a 0.95 probability of contributing less than
8.6 and 2.7 ID IC in tg338 per mL of blood respectively.
The infectivity in WBC was measured by end point dilution
titration by IC inoculation of ten folds serial dilutions in tg338
mice (Table 4). Titers calculated by the Spearman-Karber method
and expressed as the equivalent volume of whole blood ranged
between 7 and 24 ID50 IC in tg338 per mL of blood, i.e between
4.5 and 13.4 ID per mL (one ID50/mL being in average
equivalent to 0.693 ID/mL).
The infectious titers of whole blood in sheep incubating scrapie
were comparable with those previously reported in hamster and
mouse models [6,7,8,9,10]. However, these titers were at least 100
fold lower than those initially suggested by the transfusion
experiments.
Table 1. Transfusion of VRQ/VRQ sheep with blood spiked with decreasing amounts of PG127 infected sheep brain homogenate.
10
6 ID50 IC in tg338 10
5 ID50 IC in tg338 10
4 ID50 IC in tg338
10
3 ID50 IC in
tg338
10
2 ID50 IC in
tg338 10 ID50 IC in tg338
dpi PrP
Sc dpi PrP
Sc dpi PrP
Sc dpi PrP
Sc dpi PrP
Sc dpi PrP
Sc
Recipient 1 171 + 186 + 202 + 224 + .750 2. 750 2
Recipient 2 181 + 196 + 220 + .750 2. 750 2. 750 2
200 mL of whole blood was collected from each of 12 TSE Free VRQ/VRQ cheviot sheep. Whole blood pouches were spiked with decreasing amounts of sheep scrapie
strain PG127 brain homogenate containing 10
6.6 ID50/g as measured by IC inoculation in tg338 mice. Each spiked blood was then transfused back into the sheep of
origin. Two sheep were challenged at each dose (indicated as number of ID50 IC in tg338). Sheep were observed until they developed clinical signs or reached 750 days
post inoculation when they were euthanized. All recipients were tested for presence of abnormal PrP (PrP
Sc) deposition in brain and various lymphoid tissues by
immunohistochemistry. Results confirmed the clinical diagnosis. Incubation periods in recipients are presented as days post inoculation (dpi).
doi:10.1371/journal.ppat.1002782.t001
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relative abilities of whole blood, plasma and white blood cells to
transmit the disease by the transfusion route in sheep. Over
700 mL of blood was collected, few days (D4) to three weeks (D7)
before clinical onset, from each of four orally challenged VRQ/
VRQ sheep (D4 to D7) (Tables 5, 6). 500 mL of each blood was
used to prepare plasma and WBC. The WBCs were divided into
two equal parts; the first half was untreated while the other half
was fixed with PBS-paraformaldehyde (PFA). Fresh whole blood
(200 mL), fresh WBC and PFA fixed WBC (each equivalent to
200 mL of starting blood) and plasma prepared from 200 mL and
20 mL of blood were administrated intravenously to TSE free
VRQ/VRQ recipient sheep (Table 5).
Whole blood and fresh WBC produced clinical scrapie in all
recipients. The incubation periods of recipient sheep receiving
whole blood or WBC were similar suggesting comparable
virulence of both products (Table 4). In contrast, the intravenous
administration of crude plasma resulted in infection of only three
of the four recipient sheep. The incubation periods of the plasma
infections were substantially longer than in sheep who received
whole blood. None of the sheep that received plasma that had
been prepared from 20 mL of whole blood were infected. Donor
(D4), whose plasma did not transmit the disease (even when
prepared from 200 ml of whole blood), was also part of the IV
whole blood titration (Table 2) where 0.2 mL of its whole blood
was sufficient to infect the recipient. From this it can be concluded
that, in this individual, plasma was at least 10,000 fold less efficient
than whole blood for transmitting the disease by the intravenous
route.
Whereas all recipients that received fresh WBC succumbed to
clinical disease, the IV administration of PFA fixed WBCs resulted
in TSE infection of only two of four recipient sheep (Table 5) and
in incubation periods that exceeded those observed for plasma
recipients. This outcome might suggest that PFA fixation
Table 2. Titration of whole blood from PG127 scrapie infected sheep by transfusion into VRQ/VRQ TSE-free recipient sheep.
200 mL 20 mL 2 mL 0.2 mL
dpi PrP
Sc dpi PrP
Sc dpi PrP
Sc dpi PrP
Sc
D1 188 + 197 + 207 + 210 +
D2 176 + 184 + 186 + 203 +
D3 173 + 203 + 214 + .450 +
D4 169 + 178 + 193 + 214 +
Four scrapie susceptible VRQ/VRQ sheep between 6 and 10 months of age (identified as D1, D2, D3 and D4) were orally challenged with 2 grams of sheep-scrapie strain
PG127 infected brain homogenate containing 10
6.6 ID50/g as measured by IC inoculation of tg338 mice. These animals were euthanized at 227 days, 256 days, 221 days
and 226 days post inoculation (dpi) respectively with symptomatic scrapie. Scrapie infection was confirmed by histopathological detection of vacuolar changes in the
central nervous system and by immunohistochemical detection of abnormal PrP deposits in the central nervous system and lymphoid tissues. Whole blood had been
collected from each donor at 210 dpi. Donors developed clinical scrapie two to five weeks following blood collection. 200 mL, 20 mL, 2 mL and 0.2 mL were
intravenously administrated (jugular vein) to TSE Free Cheviot VRQ/VRQ recipients, within 6 hours following collection. Recipients were observed until occurrence of
clinical signs. At 450 days post inoculation the single recipient that was still alive was euthanized. This animal was clinically normal and healthy. All transfusion recipients
were tested for presence of abnormal PrP deposition in brain and various lymphoid tissues by immunohistochemistry and western blot. All recipients, including the
asymptomatic survivor to 450 days displayed evidence of infection. Incubation periods in recipients are presented as days post inoculation (dpi).
doi:10.1371/journal.ppat.1002782.t002
Table 3. Intracerebral inoculation of tg338 mice with VRQ/VRQ sheep whole blood, plasma and red blood cell concentrate.
Donor Specimen
Total inoculated volume
(equivalent whole blood)
Number of
inoculated mice
Number of
positive mice
ID per mL of
whole blood
D1 Whole blood 360 mL 18 5/18 16.3 (5.8–31.6)
Plasma 529 mL 18 1/18 1.9 (0.1–8.6)
RBC 1125 mL 18 0/18 0 (0–2.7)
D2 Whole blood 360 mL 18 2/18 5.9 (1–18.2)
Plasma 474 mL 18 0/18 0 (0–6.3)
RBC 1500 mL 18 0/18 0 (0–2)
D3 Whole blood 360 mL 18 1/18 2.9 (0.2–12.6)
Plasma 507 mL 18 0/18 0 (0–6)
RBC 1241 mL 18 0/18 0 (0–2.5)
C1 Whole blood 360 mL 18 0/18 -
Blood was collected from three TSE free VRQ/VRQ donor sheep that had been orally challenged with PG127 scrapie (D1, D2, D3) and one TSE free VRQ/VRQ control
sheep (C1). The date of collection from the infected animals was 210 days post inoculation. Donors developed clinical scrapie two to five weeks following blood
collection. They were euthanized at 227 days, 256 days, 221 days respectively. Whole blood, plasma, red blood cell concentrate (RBC) were each inoculated
intracerebrally into 18 tg338 mice (20 mL per mouse). For each component, the volume of whole blood corresponding to the volume inoculated is given. Mice were
euthanized when they showed clinical signs of infection or after 250 dpi. Mice were considered infected when abnormal PrP depositions were detected in brain.
Infectious titers were estimated using limiting dilution titration method (application of Poisson model) described by Brown et al [23]. Infectious titers are given as the
most likely infectious titer and, in parentheses, the values of the lower and upper limits of the 95% confidence interval.
doi:10.1371/journal.ppat.1002782.t003
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IC into tg338 mice, the same fresh and PFA fixed WBC
homogenates produced 100% attack rates with similar incubation
periods for both groups (Table 6). The end point titration by IC
inoculation in tg338 of PFA fixed and fresh WBC homogenates
from two of these donors (D4 and D7) further confirmed that the
fixation procedure we applied did not substantially affected the
WBC’s infectious titer (Table 6).
Discussion
Using TSE infection in sheep as a model, we have shown that
the intravenous administration of a few hundred microliters of
blood is sufficient to infect a transfusion recipient. This high
efficiency of transmission by blood transfusion contrasts with the
very low infectious titer measured by IC inoculation of blood into
transgenic mice expressing ovine PrP.
This discrepancy shows that the infectious titer as determined
by IC inoculation of rodents does not accurately predict the ability
of blood and blood-derived products to transmit the disease when
administered by the intravenous route. Importantly, this finding
indicates that assessments of transfusion transmission risks from v-
CJD that are based on IC measurements in rodents may seriously
underestimate the risk.
Our results indicate that freshly prepared WBCs have a
comparable capacity to whole blood to infect transfusion
Table 4. Tg338 mice intracerebral inoculation with VRQ/VRQ sheep white blood cells homogenates.
Donor Specimen
Total inoculated volume
(equivalent whole blood) Number of positive mice
ID50 per mL of whole
blood
D1 WBC neat 9.8 mL 6/6
WBC 1/10 980 mL 4/6 19.4 (5.5–67.8)
WBC 1/100 98 mL2 / 6
WBC 1/1000 9.8 mL0 / 6
D2 WBC neat 9.6 mL 6/6
WBC 1/10 960 mL 4/6 13.5 (4.3–41.6)
WBC 1/100 96 mL1 / 6
WBC 1/1000 9.6 mL0 / 6
D3 WBC neat 9,2 mL 6/6
WBC 1/10 920 mL 3/6 6.5 (2.5–16.7)
WBC 1/100 92 mL0 / 6
C1 WBC neat 9.7 mL 0/6 -
Blood was collected from three TSE free VRQ/VRQ donor sheep that had been orally challenged with PG127 scrapie (D1, D2, D3) and one TSE free VRQ/VRQ control
sheep (C1). The date of collection from the infected animals was 210 days post inoculation. Donor sheep developed clinical signs within two to five weeks following
blood collection. They were euthanized at 227 days, 256 days, 221 days respectively White blood cells (WBC) were prepared from whole blood and homogenised in 5%
glucose solution. Successive 1/10 dilutions of WBC homogenates were inoculated intra-cerebrally to tg338 mice (n=6). The equivalent volume of whole blood
inoculated in mice is indicated. Mice were euthanized when they showed clinical signs of infection or after 250 dpi. Mice were considered infected when abnormal PrP
depositions were detected in brain. Infectious titer was estimated by the Spearman-Karber method [19]. Infectious titer is expressed as number of ID50 per mL of whole
blood. For each samples, the most likely value and (in parentheses) the lower and upper value of the 95% confidence interval are reported.
doi:10.1371/journal.ppat.1002782.t004
Table 5. Intravenous administration in sheep and intracerebral challenge in tg338 mice of blood derived products prepared from
PG127 scrapie infected sheep.
IV administration in sheep
Whole blood Plasma (200 mL) Plasma (20 mL) Fresh WBC WBC fixed in 2% PFA
dpi PrP
Sc dpi PrP
Sc dpi PrP
Sc dpi PrP
Sc dpi PrP
Sc
D4 181 + .450 2. 380 2 184 + .450 2
D5 177 + 235 + NA 179 + 251 +
D6 167 + 259 + .380 2 181 + .450 2
D7 168 + 199 + .380 2 169 + 215 +
Four scrapie-susceptible VRQ/VRQ sheep (identified as D4, D5, D6 and D7) were orally challenged with 1 g of sheep scrapie strain PG127 infected brain homogenate
containing 10
6.7 IC ID50/g as measured by IC inoculation of tg338 mice Scrapie incubation periods were 226 dpi, 238 dpi, 228 dpi and 242 dpi, respectively. Blood was
collected at 217 dpi, i.e few days (D4) to three weeks (D7) before clinical onset. Plasma and white blood cells (WBC) were prepared from 500 mL of whole blood. Half of
the WBC preparation from each animal was fixed with paraformaldehyde (PFA 2% final concentration). Whole Blood, plasma and both fresh and fixed WBCs (re-
suspended in 5% glucose), each corresponding to 200 mL of whole blood, were administered intravenously to VRQ/VRQ TSE free recipients. In addition, Plasma volume
equivalent to 20 mL of whole blood was also intravenously administered to sheep. Recipients were euthanized when symptomatic with scrapie. 450 dpi (or 380 dpi for
the 20 mL plasma) recipients that were still alive and apparently healthy were euthanized. Incubation periods in recipients are presented in days post inoculation (dpi).
All recipient sheep were tested for the presence of abnormal PrP deposition in brain and various lymphoid tissues by immunohistochemistry.NA: not assessed.
doi:10.1371/journal.ppat.1002782.t005
New Insights in TSE Blood-Borne Transmission Risk
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their ability to transmit the disease intravenously. Tissue fixation
with aldehydes is classically described to reduce by several log10
the TSE infectivity titer (as measured by IC inoculation in rodents)
[24,25]. However this activity is dependent on the fixation
procedure and in particular on its duration. For instance, while
the fixation of a 263 K scrapie 10% brain homogenate with 3.7%
formaldehyde during 4 hours (at room temperature) resulted in a
1.58 log10 drop in the infectivity, a 30 min fixation had no
significant impact on the titer [26]. Our bioassay experiments in
tg338 mice, confirmed that the fixation procedure we applied (2%
PFA during 10 minutes on ice) preserved TSE infectivity. Beside
this, PFA fixation stabilizes cellular morphology through cross
linking of the cell surface proteins which also makes it impossible
for cells to change their cell membrane molecules and impairs
their capacity to develop dynamic cellular interactions [27,28]. We
therefore think that the ability of blood (or blood-derived products)
to transmit the disease by the transfusion route crucially depends
on the ability of blood cells to interact with the host.
This view is consistent with results obtained in in vitro prion
infection models in which cell-mediated infection was reported to
be more efficient than infection with cell homogenates or PFA
fixed cells [29,30]. It also concurs with the previously reported
ability of living splenic cells prepared from scrapie infected C57Bl6
mice to transmit scrapie in RAG-1
0/0 mice following IV
administration whereas no transmission could be observed
following the IV administration of splenic cell homogenates to
the same mouse model [31]. Whether the high capability of viable
WBC to infect blood recipients relies on the capacity of certain
cellular populations to deliver TSE agent to specific target site(s)
will require further investigation.
In the PG127 scrapie sheep model, plasma was less able than
whole blood and fresh WBCs to transmit the disease by the
transfusion route. This observation is consistent with data obtained
from similar transfusion experiments carried out in BSE infected
sheep and in Chronic Wasting Disease infected cervids [32,33].
The low transmissibility of the disease by the plasma in these
animal models contrasts with the results obtained in rodents where
plasma contains 40 to 60% of the infectivity in whole blood
[7,8,34]. Together, with the infectivity measurements that we
performed, these data support the contention that the partitioning
of TSE agents in blood components differs between sheep and
rodents models. However, the differences of infectivity load
between plasma and WBC that we observed are unlikely to
explain on their own the limited efficacy of plasma to transmit the
disease (by comparison to whole blood and WBC). This statement
is strongly supported by the WBC fixation experiment that we
performed in which the PFA treatment did not alter WBCs
infectious titer but reduced their capacity to transmit the disease to
recipients at level which is comparable to plasma.
In this study, labile blood products containing viable WBC
presented the greatest risk of transmitting Prion disease. This
finding strongly supports the continuation of universal leuco-
reduction as currently applied in the EU countries and Canada to
reduce, amongst other potential adverse effects, the risk of v-CJD
transmission [34]. Additional experiments will be necessary to
determine the minimal number of WBC (leukocytes and/or
platelets) that is sufficient to transmit the disease and to identify the
WBC cell population(s) responsible for virulence.
Finally, our results also raise some concerns about the use of the
‘spiking’ models for investigation of blood-borne TSE transmission
risk [35,36]. Whereas this approach is very convenient to measure
the TSE infectivity reduction by certain process, it is probably of
limited relevance for assessing the efficacy of devices intended to
mitigate the risk of Prion disease transmission by blood and blood
derived products.
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